Pharmaceutical composition containing arazyme for the prevention of liver dysfunction

Abstract

The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.

1 . A pharmaceutical composition for the prevention of liver dysfunction containing arazyme as an active ingredient. 
     
     
         2 . The pharmaceutical composition for the prevention of liver dysfunction according to  claim 1 , wherein the arazyme is one of:
 (a) the polypeptide harboring the amino acid sequence represented by SEQ. ID. NO: 1;   (b) the polypeptide having at least 70% homology with the sequence represented by SEQ. ID. NO: 1 and equal biological functions as the polypeptide of (a); and   (c) the polypeptide which is biologically same as the polypeptide of (a) comprising the amino acid sequence represented by SEQ. ID. NO: 1 but modified by the substitution, deletion, addition and/or insertion of one or more amino acids therein.   
     
     
         3 . The pharmaceutical composition for the prevention of liver dysfunction according to  claim 1 , wherein the arazyme is isolated from the  Aranicola proteolyticus  culture solution. 
     
     
         4 . The pharmaceutical composition for the prevention of liver dysfunction according to  claim 3 , wherein the  Aranicola proteolyticus  is  Aranicola proteolyticus  HY-3 (Accession No: KCTC 0268BP). 
     
     
         5 . The pharmaceutical composition for the prevention of liver dysfunction according to any of  claim 1 - claim 4 , wherein the composition is used for the prevention and treatment of liver disease. 
     
     
         6 . The pharmaceutical composition for the prevention of liver dysfunction according to  claim 5 , wherein the liver disease is selected from a group consisting of acute hepatitis, chronic hepatitis, fatty liver, liver cirrhosis, hepatic coma, alcoholic liver disease and hepatoma. 
     
     
         7 . A treatment method for liver disease containing the step of administration of the effective dose of the pharmaceutical composition of  claim 1  to a liver disease patient. 
     
     
         8 . The treatment method for liver disease according to  claim 7 , wherein the liver disease is selected from a group consisting of acute hepatitis, chronic hepatitis, fatty liver, liver cirrhosis, hepatic coma, alcoholic liver disease and hepatoma. 
     
     
         9 . A health food for the prevention of liver dysfunction containing the  Aranicola proteolyticus  culture solution or arazyme isolated therefrom as an active ingredient. 
     
     
         10 . The health food for the prevention of liver dysfunction according to  claim 9 , wherein the  Aranicola proteolyticus  is  Aranicola proteolyticus  HY-3 (Accession No: KCTC 0268BP). 
     
     
         11 . The health food for the prevention of liver dysfunction according to  claim 9 , wherein the arazyme is one of:
 (a) the polypeptide harboring the amino acid sequence represented by SEQ. ID. NO: 1;   (b) the polypeptide having at least 70% homology with the sequence represented by SEQ. ID. NO: 1 and equal biological functions as the polypeptide of (a); and   (c) the polypeptide which is biologically same as the polypeptide of (a) comprising the amino acid sequence represented by SEQ. ID. NO: 1 but modified by the substitution, deletion, addition and/or insertion of one or more amino acids therein.   
     
     
         12 . The health food for the prevention of liver dysfunction according to any of  claim 9 - claim 11 , wherein the health food is used to prevent and improve liver disease. 
     
     
         13 . The health food for the prevention of liver dysfunction according to  claim 12 , wherein the liver disease is selected from a group consisting of acute hepatitis, chronic hepatitis, fatty liver, liver cirrhosis, hepatic coma, alcoholic liver disease and hepatoma. 
     
     
         14 . An apoptosis inhibitor containing arazyme as an active ingredient. 
     
     
         15 . A P-smad3 expression inhibitor containing arazyme as an active ingredient. 
     
     
         16 . A liver cell injury inhibitor targeting the liver cells around central vein region containing arazyme as an active ingredient.